A Novel Guardian of Telomeres: RIOK2 Regulates Telomerase Activity Through TRiC and Dyskerin Complexes

Telomeres are repetitive DNA sequences located at chromosomal ends that are crucial for maintaining genomic stability. Telomere lengths are tightly regulated under physiological conditions, disruption of which results in telomere shortening that ultimately leads to telomere biology disorders, such as Dyskeratosis congenita (DC), bone marrow failure syndromes, and Idiopathic Pulmonary Fibrosis (IPF), amongst others. Progressive telomere shortening is also a well-recognized feature of aging. Although telomere shortening and anemia often go hand-in-hand in aging individuals and Myelodysplastic Syndrome (MDS) patients, the mechanistic link in between these manifestations remains poorly understood. In this regard, RIOK2 has recently emerged as a key transcriptional regulator of both blood cell development and telomerase activity. This commentary elaborates the multifaceted roles of RIOK2 in maintaining hematopoiesis and telomere length homeostasis in the context of aging, MDS and IPF, and further explores the potential of regulating RIOK2’s expression and/or function for therapeutic applications.

• Publication year

  2025

• Venue

  Journal of cellular immunology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.33696/immunology.7.216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening

  2024influential reference
• Imetelstat: First Approval

  2024cited by this paper
• RIO-kinase 2 is essential for hematopoiesis

  2024influential reference
• Unlocking longevity: the role of telomeres and its targeting interventions

  2024cited by this paper
• Telomere biology: from disorders to hematological diseases

  2023cited by this paper
• [Molecular international prognostic scoring system for myelodysplastic syndromes].

  2023cited by this paper
• Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.

  2023influential reference
• Leucocyte telomere length, brain volume and risk of dementia: a prospective cohort study

  2023cited by this paper
• Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

  2023cited by this paper
• Telomere biology disorders: time for moving towards the clinic?

  2022cited by this paper
• RIOK2 Contributes to Cell Growth and Protein Synthesis in Human Oral Squamous Cell Carcinoma

  2022cited by this paper
• The importance of critically short telomere in myelodysplastic syndrome

  2022cited by this paper
• Genetics of human telomere biology disorders

  2022cited by this paper
• Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.

  2022cited by this paper
• Telomere dysfunction in ageing and age-related diseases

  2022cited by this paper
• Telomerase Regulation: A Role for Epigenetics

  2021cited by this paper
• Identification of RIOK2 as a master regulator of human blood cell development

  2021cited by this paper
• Telomere biology disorders

  2021cited by this paper
• The clinical and functional effects of TERT variants in myelodysplastic syndrome

  2021cited by this paper
• Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias

  2021influential reference
• Novel combinations to improve hematopoiesis in myelodysplastic syndrome

  2020cited by this paper
• Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome.

  2020cited by this paper
• Age-associated telomere attrition in adipocyte progenitors predisposes to metabolic disease

  2020cited by this paper
• Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

  2020cited by this paper
• Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.

  2020cited by this paper
• Myelodysplastic syndromes: moving towards personalized management

  2020cited by this paper
• Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells.

  2020cited by this paper
• Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks

  2020cited by this paper
• Telomeres and telomerase: three decades of progress

  2019cited by this paper
• N-terminal residues of human dyskerin are required for interactions with telomerase RNA that prevent RNA degradation

  2019cited by this paper
• Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players

  2019cited by this paper
• Long telomeres and cancer risk: the price of cellular immortality.

  2019cited by this paper
• An Activity Switch in Human Telomerase Based on RNA Conformation and Shaped by TCAB1.

  2018cited by this paper
• Association between leukocyte telomere length and angiogenic cytokines in knee osteoarthritis

  2017cited by this paper
• Treating Cancer by Targeting Telomeres and Telomerase

  2017cited by this paper
• Impaired telomere length and telomerase activity in peripheral blood leukocytes and granulosa cells in patients with biochemical primary ovarian insufficiency.

  2017cited by this paper
• Systematic analysis of telomere length and somatic alterations in 31 cancer types

  2017cited by this paper
• A balance between elongation and trimming regulates telomere stability in stem cells

  2016cited by this paper
• Bone marrow failure and the telomeropathies.

  2014cited by this paper
• [Treatment of MDS].

  2014cited by this paper
• Lung transplantation in telomerase mutation carriers with pulmonary fibrosis

  2014cited by this paper
• Proteostatic control of telomerase function through TRiC-mediated folding of TCAB1.

  2014influential reference
• Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes.

  2014cited by this paper
• Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.

  2013cited by this paper
• Telomeres and age-related disease: how telomere biology informs clinical paradigms.

  2013cited by this paper
• The kinase activity of human Rio1 is required for final steps of cytoplasmic maturation of 40S subunits

  2012cited by this paper
• STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF.

  2012cited by this paper
• [Management of patients with lower risk myelodysplastic syndromes].

  2012cited by this paper
• Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide

  2012cited by this paper
• Telomerase: an RNP enzyme synthesizes DNA.

  2011cited by this paper
• Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita.

  2011cited by this paper
• Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita

  2011cited by this paper
• Behaviour of Telomere and Telomerase during Aging and Regeneration in Zebrafish

  2011cited by this paper
• Normal mammalian cells negatively regulate telomere length by telomere trimming.

  2011cited by this paper
• Imetelstat (GRN163L)--telomerase-based cancer therapy.

  2010cited by this paper
• A Human Telomerase Holoenzyme Protein Required for Cajal Body Localization and Telomere Synthesis

  2009cited by this paper
• Expression of Telomerase and Telomere Length Are Unaffected by either Age or Limb Regeneration in Danio rerio

  2009cited by this paper
• Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.

  2003cited by this paper
• Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression.

  2001cited by this paper
• Control of Human Telomere Length by TRF1 and TRF2

  2000cited by this paper
• Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.

  1999cited by this paper
• A telomerase component is defective in the human disease dyskeratosis congenita

  1999cited by this paper
• Unusual complications after bone marrow transplantation for dyskeratosis congenita

  1998cited by this paper
• Control of telomere length by the human telomeric protein TRF1

  1997cited by this paper
• Telomere length in myelodysplastic syndromes

  1997cited by this paper
• Hypervariable ultra-long telomeres in mice

  1990cited by this paper

• No citing papers are available for this paper.